Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Juno Therapeutics (JUNO)

Juno Therapeutics (JUNO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,096,926
  • Shares Outstanding, K 116,110
  • Annual Sales, $ 79,360 K
  • Annual Income, $ -245,580 K
  • 60-Month Beta 3.24
  • Price/Sales 82.93
  • Price/Cash Flow N/A
  • Price/Book 9.58
Trade JUNO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.25
  • Most Recent Earnings -0.73 on 11/01/17
  • Next Earnings Date 03/07/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/17
See More
  • Average Estimate -1.13
  • Number of Estimates 4
  • High Estimate -0.67
  • Low Estimate -1.59
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -71.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.77 +2.58%
on 02/20/18
87.01 -0.06%
on 03/05/18
+1.34 (+1.57%)
since 02/05/18
3-Month
42.29 +105.63%
on 12/19/17
87.01 -0.06%
on 03/05/18
+33.76 (+63.46%)
since 12/05/17
52-Week
19.62 +343.22%
on 03/27/17
87.01 -0.06%
on 03/05/18
+65.35 (+302.41%)
since 03/03/17

Most Recent Stories

More News
Alexandria Venture Investments Recognized as #1 Most Active Biopharma Investor for Third Consecutive Year

, /PRNewswire/ -- Alexandria Venture Investments, the strategic venture capital platform of Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the first, longest-tenured and...

JUNO : 86.96 (+0.10%)
ARE : 162.14 (-0.27%)
USIJ Releases Report on The Importance of an Effective and Reliable Patent System to Critical Technologies

, /PRNewswire/ -- Today, the Alliance of U.S. Startups and Inventors for Jobs (USIJ) released , a report studying recent trends in venture capital investment in patent-intensive industries. It was authored...

GT : 10.95 (-0.64%)
JUNO : 86.96 (+0.10%)
Global CAR T Cell Therapy Market to 2026 - by Regions, Targeted Antigens, Clinical Trials/Study & Companies - ResearchAndMarkets.com

The "CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies" report has been added to ResearchAndMarkets.com's offering.

CELGZ : 0.47 (+2.15%)
CYAD : 9.95 (+3.32%)
GILD : 60.03 (+0.89%)
JUNO : 86.96 (+0.10%)
KITE : 179.99 (+0.11%)
NVS : 89.76 (+0.65%)
CAR-T Therapy Market Outlook to 2030 by Target Antigen, Application, Region, Country and Company

, /PRNewswire/ -- The report has been added to offering.

CELGZ : 0.47 (+2.15%)
JUNO : 86.96 (+0.10%)
KITE : 179.99 (+0.11%)
NVS : 89.76 (+0.65%)
PFE : 37.23 (+1.92%)
SRNE : 8.15 (+18.12%)
Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors

Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company's proprietary engineered toxin bodies (ETBs), which are differentiated,...

CELGZ : 0.47 (+2.15%)
JUNO : 86.96 (+0.10%)
MTEM : 9.12 (+3.17%)
State Street Global Advisors Announces Impact of Receiving Payment

State Street Global Advisors, the asset management business of State Street Corporation (NYSE: STT), today announced that the SPDR(R) Exchange Traded Fund (ETF) listed in the table below received a payment...

STT : 71.59 (-0.90%)
JUNO : 86.96 (+0.10%)
CELG : 108.24 (+0.10%)
GRAIL Announces Appointment of Hans Bishop as Chief Executive Officer and Strengthens Leadership Team and Board of Directors with New Appointments

-- Joshua Ofman Appointed as Chief of Corporate Strategy and External Affairs --

JUNO : 86.96 (+0.10%)

Business Summary

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms - Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult...

See More

Key Turning Points

2nd Resistance Point 87.07
1st Resistance Point 87.01
Last Price 86.96
1st Support Level 86.90
2nd Support Level 86.85

See More

52-Week High 87.01
Last Price 86.96
Fibonacci 61.8% 61.27
Fibonacci 50% 53.32
Fibonacci 38.2% 45.36
52-Week Low 19.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar